Amgen (AMGN) presented results at the 2019 European Society for Medical Oncology ((ESMO)). It presented results from its phase 1 study using AMG 510 to treat patients with a few solid tumors. Specifically, these were in colorectal cancer, appendiceal cancer, and prior reported non-small cell lung cancer ((NSCLC)). The data from patients with colorectal cancer and appendiceal cancer was mixed. They were decent, but not as strong as the prior showing in NSCLC patients. Still, this is a new territory that is being explored in terms of treating cancers within the specific KRAS